Comparing two types of gastric bypass for obesity treatment
Official title: A Multicentre Randomized Controlled Trial Comparing Outcome of Laparoscopic One-anastomosis Gastric Bypass and Laparoscopic Long Biliopancreatic Limb Roux Gastric Bypass for Treatment of Morbid Obesity.
Run by Tartu University Hospital · NCT04812132 · Data updated 2026-11-12
This study is testing which type of gastric bypass surgery, one-anastomosis or long biliary limb Roux, works better for people with obesity to help them lose weight and improve their health over time.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Tartu University Hospital Academic / other |
| Locations | 1 site (Tartu) |
| Status | Recruiting |
| Started | January 1, 2021 |
| Main results expected | December 31, 2031 |
| Study ends | December 31, 2036 |
| Registry record updated | March 23, 2021 |
| Trial ID | NCT04812132 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-60 with a BMI over 35 and obesity-related diseases or a BMI over 40.
✕Probably not a fit
Patients under 18 or over 60 years old, those with prior bariatric surgery, or those with active gastrointestinal or psychiatric conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a prospective multicenter randomized controlled trial designed to compare the outcomes of one-anastomosis gastric bypass (OAGB) with long biliary limb Roux gastric bypass in patients suffering from obesity. The study aims to enroll up to 500 patients across three clinics in Estonia and will evaluate various outcomes including excess weight loss percentage, effects on type 2 diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea. Additionally, it will assess nutritional deficiencies, reflux disease occurrence, and quality of life impacts over a follow-up period of 1, 5, and 10 years post-surgery.
Why it matters
Potential benefit: If successful, this study could provide insights into which surgical approach offers better outcomes for patients with obesity and related health conditions.
How similar studies have gone: While many studies have compared OAGB to standard Roux gastric bypass, this study is novel as it specifically compares OAGB to long biliary limb gastric bypass.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI over 35 and obesity related disease * BMI over 40 * age between 18-60 years * agrees to participate in the study Exclusion Criteria: * age under 18 years or over 60 years * abundant adhesions discovered during the surgery * active upper gastrointestinal ulcer disease * prior bariatric surgery * active symptomatic reflux disease * active psychiatric disease (eg psychosis)
Where it's running
-
Tartu University Hospital
Tartu, Estonia Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.